Bartek Ingredients Purchases New State-of-the-Art Maleic Anhydride Reactor
3.9.2019 18:25:00 EEST | Business Wire | Press release
On the heels of its successful expansion of its malic and fumaric acid finishing capacity earlier in 2019, Bartek Ingredients announced the decision to purchase a 22,000 metric tons/year reactor from MAN Energy Solutions in Deggendorf, Germany.
The reactor will expand the company’s maleic anhydride capacity ahead of anticipated long-term growth in the global acidulants market. It further integrates Bartek’s upstream raw material production with its downstream finishing capacity.
“The new reactor will be a welcome addition to the North American market, where additional capacity is projected to be required by 2023,” Bartek CEO John Burrows said. “Bartek is committed to leading the global market in malic and food grade fumaric acid, and ensuring that our customers are supplied for years to come is a vital element of our long-term strategy.”
Bartek expects delivery of this new reactor in Q4 2020 with the capacity to be online in Q2 2021.
“This investment decision by the Bartek board supports the company’s strategy of investing ahead of market demand and reinforces the company’s objective to operate a best-in-class manufacturing operation,” said Matt Chapman, partner at Bartek’s parent company, TorQuest Partners.
For more information about Bartek and its products, visit bartek.ca.
About Bartek Ingredients
Established in 1969, Bartek Ingredients Inc. is a leading producer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. For more information about Bartek, visit bartek.ca/.
About TorQuest Partners
Founded in 2002, TorQuest Partners is a Canadian-based manager of private equity funds. With more than C$2 billion of equity capital under management, TorQuest invests in middle market companies and works in close partnership with management to build value. To learn more about TorQuest Partners, visit torquest.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005672/en/
Contact information
Erin Robbins
MarketPlace
erin.robbins@market-pl.com
+1-314-366-3562
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom